Plus therapeutics presents positive respect-lm clinical trial results of reyobiq™ in leptomeningeal metastases

Reyobiq produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures rna sequencing and circulating tumor cell reduction consistent with tumor cell death no dose limiting toxicities were observed with an overall favorable safety profile houston, aug. 18, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, announces positive data from the respect-lm phase 1 single dose escalation trial presented at the podium at the sno/asco cns metastases conference in baltimore, md. the data demonstrated treatment of leptomeningeal metastases (lm) with reyobiq is feasible, has a manageable safety profile, and shows a promising efficacy signal.
PSTV Ratings Summary
PSTV Quant Ranking